Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRenalytix Plc Regulatory News (RENX)

Share Price Information for Renalytix Plc (RENX)

Share Price is delayed by 15 minutes
Get Live Data
1.85    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.30 (17.647%)
Market Cap: £8.08m
RENX Live PriceLast checked at - London Stock Exchange

Intraday Renalytix Plc Share Chart

Form 8.5 (EPT/RI)-Renalytix Plc

17 Jun 2024 10:08

Form 8.5 (EPT/RI)-Renalytix Plc

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Name of exempt principal trader:Investec Bank plc
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeRenalytix plc
(c) Name of the party to the offer with which exempt principal trader is connected:Investec is Joint Broker to Renalytix plc
(d) Date dealing undertaken: 14th June 2024
(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchases/ sales Total number of securitiesHighest price per unit paid / received (pence)Lowest price per unit paid / received (pence)
Ordinary Shares Purchase 21,888 18.98 18.725

(b) Cash-settled derivative transactions

Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit
        

(ii) Exercise

Class of relevant securityProduct description e.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
     

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable)
    

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”
 

Date of disclosure:17th June 2024
Contact name:Abhishek Gawde
Telephone number:+91 9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Date   Source Headline
30th Oct 20254:58 pmRNSHolding(s) in Company
28th Oct 20254:04 pmRNSHolding(s) in Company
27th Oct 20257:00 amRNSConfirmation of receipt of £860k R&D tax credits
24th Oct 202510:12 amRNSHolding(s) in Company
23rd Oct 20259:09 amRNSHolding(s) in Company
21st Oct 202510:08 amRNSHolding(s) in Company
17th Oct 202510:26 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSHolding(s) in Company
16th Oct 20252:31 pmRNSHolding(s) in Company
16th Oct 202512:15 pmRNSHolding(s) in Company
15th Oct 20259:48 amRNSHolding(s) in Company
10th Oct 20252:34 pmRNSHolding(s) in Company
10th Oct 20259:56 amRNSHolding(s) in Company
10th Oct 20257:01 amRNSHolding(s) in Company
10th Oct 20257:00 amRNS$4m balance sheet improvement with bond conversion
9th Oct 20254:43 pmRNSHolding(s) in Company
7th Oct 20253:03 pmRNSHolding(s) in Company
3rd Oct 20252:32 pmRNSHolding(s) in Company
2nd Oct 20252:57 pmRNSHolding(s) in Company
1st Oct 20252:43 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
1st Oct 20257:00 amRNSCE Mark application submission
30th Sep 20254:02 pmRNSHolding(s) in Company
29th Sep 20255:18 pmRNSHolding(s) in Company
29th Sep 20252:28 pmRNSHolding(s) in Company
29th Sep 20259:32 amRNSHolding(s) in Company
29th Sep 20257:00 amRNSHolding(s) in Company
26th Sep 202512:17 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNS£7.05m total gross proceeds from Fundraise
24th Sep 20252:00 pmRNSUpdate Regarding Forward Guidance
24th Sep 202510:00 amRNSAdditional Subscription for 11m Shares
23rd Sep 20257:00 amRNSInvestor Presentation and Revised Revenue Guidance
22nd Sep 20255:30 pmRNSResult of Fundraise
22nd Sep 20257:01 amRNSWRAP Retail Offer for up to £500,000
22nd Sep 20257:00 amRNSProposed Fundraise
17th Sep 20257:00 amRNSHolding(s) in Company
16th Sep 20256:26 pmRNSHolding(s) in Company
16th Sep 20257:00 amRNSHolding(s) in Company
15th Sep 20257:00 amRNSTempus AI Inc, collaboration agreement
11th Sep 20255:14 pmRNSHolding(s) in Company
10th Sep 20254:32 pmRNSHolding(s) in Company
2nd Sep 202512:46 pmRNSHolding(s) in Company
1st Sep 202511:18 amRNSHolding(s) in Company
29th Aug 20259:25 amRNSHolding(s) in Company
26th Aug 202511:45 amRNSHolding(s) in Company
22nd Aug 20255:11 pmRNSHolding(s) in Company
22nd Aug 20251:30 pmRNSHolding(s) in Company
29th Jul 20257:00 amRNSServices contract with Joslin and Pharma Partner
17th Jul 20257:01 amRNSPartnership with MVP Health Care
17th Jul 20257:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.